Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
Wayne Vuong, Conrad Fischer, Muhammad Bashir Khan, Marco J. van Belkum, Tess Lamer, Kurtis D. Willoughby, Jimmy Lu, Elena Arutyunova, Michael Joyce, Holly A. Saffran, Justin Shields, Howard S. Young, James A. Nieman, D. Lorne Tyrrell, M. Joanne Lemieux, John C. Vederas
Topics & Concepts
ChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DrugProteaseCoronavirusAntiviral drug2019-20 coronavirus outbreakVirologySolubilityCoronavirus disease 2019 (COVID-19)PharmacologyEnzyme inhibitorViral replicationEnzymeBiochemistryVirusOrganic chemistryInfectious disease (medical specialty)BiologyOutbreakPathologyDiseaseMedicineComputational Drug Discovery MethodsPharmacological Effects of Natural CompoundsSARS-CoV-2 and COVID-19 Research